ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P 500
5,195.52
0.15%
US Tech 100
17,591.20
-0.06%
Dow Jones
39,209.77
0.39%
Brent Oil
83.765
0.25%
Bitcoin
61,251.88
0.11%
Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Altimmune Inc (ALT) Quote

Altimmune Inc

Altimmune Inc (ALT)

Analytica Limited
Altitude Group Plc
Alturas Minerals Corp
7.92
0.76
( 10.61% )
Updated: 10:11:05
Delayed by 15 minutes

Empower your portfolio: Real-time discussions and actionable trading ideas.

Premium

Key stats and details

Current Price
7.92
Bid
7.90
Ask
7.92
Volume
1,226,242
7.17 Day's Range 8.0751
2.09 52 Week Range 14.84
Market Cap
423.921M
Previous Close
7.16
Open
7.22
Last Trade
1
@
7.92
Last Trade Time
10:11:05
Financial Volume
$ 9,351,480
VWAP
7.6261
Average Volume (3m)
4,374,266
Shares Outstanding
53,728,871
Dividend Yield
-
PE Ratio
-4.79
Earnings Per Share (EPS)
-1.65
Revenue
426k
Net Profit
-88.45M

About Altimmune Inc

Altimmune Inc is a clinical-stage biopharmaceutical company focused on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the tre... Altimmune Inc is a clinical-stage biopharmaceutical company focused on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH (non-alcoholic steatohepatitis). In addition, Altimmune is developing HepTcell, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B virus (HBV). Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
www.altimmune.com
Headquarters
Wilmington, Delaware, USA
Founded
1970
Altimmune Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker ALT. The last closing price for Altimmune was $7.16. Over the last year, Altimmune shares have traded in a share price range of $ 2.09 to $ 14.84.

Altimmune currently has 53,728,871 shares outstanding. The market capitalization of Altimmune is $423.92 million. Altimmune has a price to earnings ratio (PE ratio) of -4.79.

Altimmune (ALT) Options Flow Summary

ALT Options Flow

Overall Flow

Bullish

Net Premium

112k

Calls / Puts

100.00%

Buys / Sells

50.00%

OTM / ITM

100.00%

Sweeps Ratio

0.33%

ALT Latest News

More News

Form 8-K - Current report

3 hours ago
Edgar (US Regulatory)

Altimmune Announces First Quarter 2024 Financial Results and Provides a Business Update

Enrollment ongoing in IMPACT Phase 2b trial of pemvidutide in Metabolic Dysfunction-Associated Steatohepatitis (MASH), with top line results expected in Q1 2025 Cash, cash equivalents and...

3 hours ago
GlobeNewswire Inc.

Altimmune to Participate at Two Upcoming Investor Conferences

GAITHERSBURG, Md., May 07, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Companyā€™s management team will...

May 07 2024
GlobeNewswire Inc.

Altimmune to Report First Quarter 2024 Financial Results and Provide Business Update on May 9, 2024

GAITHERSBURG, Md., May 02, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its first quarter 2024...

May 02 2024
GlobeNewswire Inc.

Altimmune to Participate at Two Upcoming Conferences

GAITHERSBURG, Md., May 01, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that Dr. Scott Harris, Chief Medical Officer at...

May 01 2024
GlobeNewswire Inc.

Altimmune Statement on the Passing of Dr. Stephen Harrison

GAITHERSBURG, Md., April 25, 2024 (GLOBE NEWSWIRE) -- The Altimmune team would like to express our sorrow and extend our heartfelt condolences to Dr. Stephen Harrisonā€™s family following his...

April 25 2024
GlobeNewswire Inc.

Altimmune Announces Positive Lean Mass Preservation Data for Pemvidutide and Reports Fourth Quarter and Full Year 2023 Financial Results

Body composition study showed lean mass preservation, with only 25.5% of weight loss derived from lean mass Enrollment ongoing in IMPACT Phase 2b trial of pemvidutide in Metabolic...

March 27 2024
GlobeNewswire Inc.

U.S. Stock Index Futures Point to a Rebound, Oil See Declines in Early Trading

U.S. index futures indicate an uptrend in pre-market trading on Wednesday, bouncing back after a previous unfavorable session that further distanced the indices from reaching their record levels...

March 27 2024
IH Market News

Altimmune to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on March 27, 2024

GAITHERSBURG, Md., March 20, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its fourth quarter and full...

March 20 2024
GlobeNewswire Inc.

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]

February 14 2024
Edgar (US Regulatory)
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.7410.30640668527.188.07516.8124924827.22960095CS
4-0.15-1.858736059488.078.546.28229578537.21111265CS
12-1.03-11.50837988838.9514.846.28243742669.75445321CS
265.21192.2509225092.7114.842.31579486688.0113169CS
523.0161.30346232184.9114.842.0946860237.27160006CS
156-5.76-42.105263157913.6823.492.0925793448.85078843CS
2604.99170.3071672352.9335.11.45215938010.11793824CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
CPOPPop Culture Group Company Ltd
$ 3.3699
(98.23%)
53.37M
SEZLSezzle Inc
$ 75.56
(68.89%)
284.56k
EMBCEmbecta Corporation
$ 14.22
(38.46%)
786.3k
NTBLNotable Labs Ltd
$ 1.61
(35.29%)
2.08M
CCSIConcensus Cloud Solutions Inc
$ 17.64
(33.33%)
157.81k
EMKREMCORE Corporation
$ 1.1101
(-61.72%)
2.12M
TIVCTivic Health Systems Inc
$ 0.5245
(-60.86%)
4.91M
CDLXCardlytics Inc
$ 8.26
(-43.42%)
3.81M
CTMXCytomX Therapeutics Inc
$ 2.4591
(-41.31%)
13.41M
RAPTRAPT Therapeutics Inc
$ 5.16
(-35.34%)
1.61M
GWAVGreenwave Technology Solutions Inc
$ 0.0702
(20.83%)
106.13M
CPOPPop Culture Group Company Ltd
$ 3.3699
(98.23%)
53.37M
SGDSafe and Green Development Corporation
$ 0.79
(27.42%)
42.67M
SQQQProShares UltraPro Short QQQ
$ 10.755
(0.14%)
20.47M
PLUGPlug Power Inc
$ 2.60
(3.17%)
19.99M

ALT Discussion

View Posts
akamaii akamaii 2 weeks ago
Going long for a year 75 target or 50 plus
šŸ‘ļø0
Mt. Blanc Mt. Blanc 3 weeks ago
So much for my ALT prediction.

The stock slipped to $7 and may be cratering more since it's getting no love.

Maybe ALT is a $5 stock or lower if buyers aren't interested.

mb
šŸ‘ļø0
Mt. Blanc Mt. Blanc 1 month ago
Radar. ALT $11- $12

Getting picked up.

mb
šŸ‘ļø0
Monksdream Monksdream 1 month ago
ALT over $10
Next day settlement begins 5/28 per SEC mandate
šŸ‘ļø0
Monksdream Monksdream 2 months ago
ALT 10Q due 3/27
Next day settlement begins 5/28
šŸ‘ļø0
saigai saigai 2 months ago
patiently waiting.. for sure something in the way of news is right there and it can only be a plus.. i want the buyout.. let say 4 billion.. 80 bucks a share..gl
šŸ‘ļø0
Mark102 Mark102 2 months ago
Buyout? Partnership? In less than 9 trading days we will find out.
šŸ‘ļø0
Mark102 Mark102 2 months ago
BUCKLE UP. going to break 15 soon
šŸ‘ļø0
saigai saigai 2 months ago
a good read
https://www.rcplondon.ac.uk/news/world-obesity-day-let-s-talk-about-drugs
šŸ‘ļø0
saigai saigai 2 months ago
slow and steady is healthy as the data goes as well.. fast weight loss is never good and the deeper dive into the data im sure will find that Alt has a wider profile a safer profile as it relates to muscle loss and bone density. time will tell...in any case the real value here is the undiscovered uses.. wide profile more mkts...long and strong ...
šŸ‘ļø0
Mt. Blanc Mt. Blanc 2 months ago
ALT @ $12?

Interesting

mb
šŸ‘ļø0
saigai saigai 2 months ago
institutional ownership from nasdaq site
https://www.nasdaq.com/market-activity/stocks/alt/institutional-holdings
šŸ‘ļø0
saigai saigai 3 months ago
big volume wrong direction for now
šŸ‘ļø0
saigai saigai 3 months ago
a good read
https://finance.yahoo.com/news/weight-loss-drugs-patients-lose-134837816.html
šŸ‘ļø0
saigai saigai 3 months ago
and a few more...
šŸ‘ļø0
saigai saigai 3 months ago
you wont be able to chase this..you either in before the news or outside looking in.. patience of a saint..
šŸ‘ļø0
saigai saigai 4 months ago
driving me nutz but i wont sell this until !!!
šŸ‘ļø0
murocman murocman 4 months ago
Post from another board relevant to ALT:

GLP-1 drugs will_be supply-constrained for_a_few_years, according to the NVO and LLY webcasts at JPM. All in-house and CMO capacity suitable for manufacturing injected GLP-1 drugs is already in service. Moreover, the eventual uptake of oral GLP-1 drugs will not ease the manufacturing bottleneck as much as people might think because the low bioavailability of the oral agents requires large amounts of API.
šŸ‘ļø0
AGORDON AGORDON 4 months ago
Altimmune, Inc.
(Nasdaq - ALT) $12/share
Market cap = $644M
Cash = $140M
Cash Burn rate = ($76)/Y
Catalysts:
Pemvidutide - Weight loss drug. Peptide based GLP-1/Glucagon dual receptor agonist. Phase 2 results were respectable. At 48 weeks, for 2.4mg (high dose), weight loss of -15.6% (on the low end of the expected 15-20%)., but comparable to Mounjaro. The TRAEs appear to be less than Mounjaro's. The drug did reduce triglycerides.
HepTCell - an immunotherapeutic for Chronic Hepatitis B. In Phase 2 trials. Next read out could be in April, 2024.
šŸ‘ļø0
Mark102 Mark102 4 months ago
I was wrong ALT is attending the JPM Let's get this deal done.
šŸ‘ļø0
saigai saigai 4 months ago
thanks a lot.. im on a new computer.. id rather have oral surgery than learn a new computer
šŸ‘ļø0
Mark102 Mark102 4 months ago
Data is in check Twitter. Weight loss is a 100 billion market. The results on the liver data show a 100 % reduction of fat at the highest dose. That's a 40 billion market.
Now why is ALT not attending the JPM conference this week? Stay tuned
šŸ‘ļø0
saigai saigai 4 months ago
im hanging around bewteen the two potential mkts for their drug its too crazy to even think out loud lets see what the data says.. if its good or really good. all hell will break out
šŸ‘ļø0
Mark102 Mark102 4 months ago
Float is locked, tutes trying to shake few out but this is a done deal IMO
šŸ‘ļø0
saigai saigai 4 months ago
this is a powder keg...
šŸ‘ļø0
saigai saigai 4 months ago
i believe if they wanted to they could have closed a deal by now but they wait till after the new data.. i wonder why.. there is no way for this to go but way up from here..glta
šŸ‘ļø0
Mark102 Mark102 4 months ago
Been Holding since 6. Buyout or partnership is imminent.
šŸ‘ļø0
1hot toddy 1hot toddy 4 months ago
HUGE BUYS NOW 10K BUY $100K BUY $$$$$$$$$$$$$$$$$$
šŸ‘ļø0
Bud-Wiser Bud-Wiser 4 months ago
Nice comeback today -Iā€™m back in
šŸ‘ļø0
1hot toddy 1hot toddy 4 months ago
WOOOOOOOOOOOW 10K AND 9100 SHARE BUYS 2-$100,000 BUYS $$$$$$$$$$$$$$$$$$$$$$$$$$$$$
BABY MONSTER HERE
šŸ‘ļø0
eyeownu eyeownu 4 months ago
got dammmmmmmmmmm. oprah must be buying out the company
šŸ‘ļø0
1hot toddy 1hot toddy 4 months ago
WOOOOOOW 10,000 SHARE BUY $110,000 BUY $$$$$$$$$$$$$$$$
MONSTER WEIGHT LOSS CO HERE
šŸ‘ļø0
Mark102 Mark102 4 months ago
Next Gap to 19 to fill. PT 60 to 100 on a buyout
šŸ‘ļø0
1hot toddy 1hot toddy 5 months ago
WOOOOOOOOOOOW 21000 SHARE BUY OVER $150,000 BUY . KILLER WEIGHT LOSS HERE $$$$$$$$$$$
šŸ‘ļø0
eyeownu eyeownu 5 months ago
rallys over IMO. end of year.. could be wrong tho!
šŸ‘ļø0
1hot toddy 1hot toddy 5 months ago
WOOOOOOOOOOW 11000 SHARE BUY $90000 BUY WEIGHT LOSS RESULTS GREAT $$$$$
šŸ‘ļø0
1hot toddy 1hot toddy 5 months ago
HUGE BUYS 8000 SHARES PLUS BUNCH OF 4000 SHARE BUYS $$$$$$$$$
šŸ‘ļø0
1hot toddy 1hot toddy 5 months ago
WOOOOOOOW 8800 SHARE BUY $60000 BUY $$$$$$$$$4
šŸ‘ļø0
saigai saigai 5 months ago
volume still there
šŸ‘ļø0
1hot toddy 1hot toddy 5 months ago
25000 share buy plus 10k buy $$$$$$$$$$$$$$
šŸ‘ļø0
saigai saigai 5 months ago
what a day tomorrow even better
šŸ‘ļø0
1hot toddy 1hot toddy 5 months ago
you were smart to add yesterday on big down day. y wait till today on up day to add??? i added more now
šŸ‘ļø0
saigai saigai 5 months ago
buena suerte to all
šŸ‘ļø0
1hot toddy 1hot toddy 5 months ago
11000 SHARE BUY PLUS BUNCH OF 5000 SHARE BUYS $$$$$$$$$$
šŸ‘ļø0
Mark102 Mark102 5 months ago
Nice I added more yesterday. Should waited till today but still happy with my positions
šŸ‘ļø0
1hot toddy 1hot toddy 5 months ago
seems like the momentum stocks go up and down together. before phase 3 going to get alot of cash from someone who will market the product. its got great results and can be up huge within a year 5x
šŸ‘ļø0
saigai saigai 5 months ago
i think this is going be go nutz.. as posted on stockwits blackrock owns 7 percent of alt.. i own 420 shares following the money
šŸ‘ļø0
saigai saigai 5 months ago
i know im repeating myself but this is the most volatile stock ive ever owned
šŸ‘ļø0
saigai saigai 5 months ago
looks like gonna be a big day.. no charts just gut feeling
šŸ‘ļø0
gail gail 5 months ago
like clockwork, not opening the mitt yet.
šŸ‘ļø0

Your Recent History

NASDAQ
ALT
Altimmune
Delayed Upgrade Clock
ADVFN Logo

United States
Company
Business
Popular
Get The App

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved